ArticleBMC ophthalmology2026
Shallow and bullous retinal pigment epithelium elevations in age-related macular degeneration.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess prevalence and associations of shallow retinal pigment epithelium (RPE) elevations (RPEEs) and bullous RPE detachments (RPEDs).
methodsMacular optical coherence tomographic images taken in the population-based Beijing Eye Study were examined for the presence of RPEEs/RPEDs.
resultsIn the study cohort of 953 eyes (mean age:63.3 ± 9.3years), RPEE/RPED prevalence increased from 0/376 (0%) in the normal group and 0/373 (0%) in the group with early AMD stage, to 33/199 (16.6%;95%CI:11.4,21.8) and 1/5 (20.0%;95%CI:0.0,75.5) in intermediate and late AMD, respectively. In intermediate AMD, prevalences of RPEEs and RPEDs were 30/199 (15.1%;95%CI:10.0,20.2) and 9/199 (4.5%;95%CI:1.5,7.5), respectively. Higher total RPEE/RPED prevalence was associated with higher AMD stage (OR:55.3;95%CI:14.4,327;P < 0.001), higher drusen number (OR:1,05;95%%CI:1.02,1.07;P < 0.001), lower prevalence of external limiting membrane defects (OR:0.19;95%CI:0.05,0.57;P = 0.003), in addition to male sex (OR:11.0;95%CI:3.37,45.5;P < 0.001) and higher serum concentration of triglycerides (OR:1.48;95%CI:1.20,1.89;P < 0.001). RPEE/RPED prevalence was not significantly associated with choroidal thickness as a whole (P = 0.55) or separated in a large-vessel choroidal layer (P = 0.86), medium-sized vessel layer (P = 0.66) or small-vessel layer (P = 0.24), prevalence (P = 0.97) and location of any intraretinal hyperreflective foci, and prevalence of reticular pseudodrusen (P = 0.57).
conclusionsAny RPEE/RPED, RPEEs and RPEDs were found in 16.6%, 15.1% and 4.5% of eyes with intermediate AMD, respectively, with a higher RPEE/RPED prevalence correlating with higher drusen number, lower prevalence of external limiting membrane defects and higher serum concentration of triglycerides. The statistical independence of RPEEs/RPEDs from the prevalences of reticular pseudodrusen and intraretinal hyperreflective foci point to differences in their etiologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.